Clinical trials: Poor Performance Status, open to volunteers
Small-cell Lung Cancer
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
The SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2).
- Trial name
- SPACE-T (NCT07803848)
- Testing
- Tarlatamab
- Where
- 8 sites in Germany
- Volunteers
- 57 people
- Sponsor
- AIO-Studien-gGmbH
Small Cell Lung Cancer
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
This is a multicenter, single-arm, exploratory clinical study designed to observe and evaluate the efficacy and safety of adebrelimab combined with oral etoposide for elderly patients and patients with poor performance status in…
- Trial name
- NCT07398560
- Testing
- Adebrelimab, Oral etoposide soft capsules
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The Third Affiliated Hospital of Harbin Medical University
Non-Small Cell Lung Cancer (NSCLC)
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to…
- Trial name
- NCT05589818
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status
The goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and…
- Trial name
- HNSCC (NCT07796126)
- Testing
- Toripalimab, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute